![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Kbw Regional Banking Index | DOWI:KRX | Dow Jones Indices | Index |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
Keryx Biopharmaceuticals, Inc. to Present at The Bear Stearns 16th Annual Healthcare Conference NEW YORK, Sept. 5 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; AIM: KRX), a biopharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer, announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company's strategic plans and recent developments at the Bear Stearns 16th Annual Healthcare Conference in New York City. Mr. Weiss's presentation will take place on Monday, September 8, 2003, at 2:00 pm EST, in the Le Louvre Room, located on the 1st floor of the Plaza Hotel. A live audio webcast and a 60-day audio archive of the presentation will be available via the following link: http://customer.nvglb.com/BEAR002/090803a_cy/default.asp?entity=keryx About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) is a biopharmaceuticals company focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound, for the treatment of diabetic nephropathy, for which Keryx is currently planning its U.S.-based Phase II/III clinical program. Keryx also has an active in-licensing program designed to identify and acquire clinical-stage drug candidates. Additionally, Keryx is seeking partners for its KinAce(TM) drug discovery technology and related products. Keryx Biopharmaceuticals is headquartered in New York City. Contact: Ron Bentsur VP Finance and Investor Relations Keryx Biopharmaceuticals, Inc. Tel: +1-212-531-5965 E-mail: ron@keryx.com SOURCE Keryx Biopharmaceuticals, Inc. -0- 09/05/2003 /CONTACT: Ron Bentsur, VP Finance and Investor Relations of Keryx Biopharmaceuticals, Inc., +1-212-531-5965, or ron@keryx.com / (KERX) END
1 Year Kbw Regional Banking Index Chart |
1 Month Kbw Regional Banking Index Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions